31.65
-0.57%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nanjing Hicin Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300584.SZ. It has been listed since 12 January 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥671.0m and net income of CN¥42.1m. At that date it held total assets of CN¥1.53bn and shareholders' equity of CN¥1.05bn.
Nanjing Hicin Pharmaceutical Co., Ltd. engages in the manufacture, research and development of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2017-01-12. The firm's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Jan 2017
- Employees
- 549
- Website
- hicin.cn/page1/index1 ↗
Leadership
Pay as last reported
- Mr. Yuping CaoChairman of the Board, General Manager, since 2003CN¥410,800
- Mr. Jianren ChenChief Financial Officer
- Mr. Li WangDeputy General Manager, Secretary of the Board
- Mr. Mingsheng FengDeputy General Manager, Director, since 2022
- Mr. Guangyao LiuDeputy General Manager
- Mr. Weibiao YueDeputy General Manager
- Mr. Xichen CaoDirector
- Ms. Yuanhong ChuStaff Elected Director
- Mr. Tao LuIndependent Director
- Mr. Lingxiao MaoIndependent Director
- Mr. Yuchun WangIndependent Director, since 2025CN¥45,300
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 549 full-time employees
- Products include torsemide for injection and tigecycline for injection
- IPO occurred on 2017-01-12
Weaknesses
- No specific financial data provided
- No mention of market share or revenue figures
- No information on product pricing or distribution channels
Opportunities
- Products cover multiple therapeutic areas including diuresis and cardiovascular
- IPO in 2017 may provide capital for expansion
- Headquartered in Nanjing, Jiangsu with potential for regional growth
Threats
- No information on competition or market saturation
- No data on regulatory challenges or approval processes
- No mention of potential product recalls or safety issues
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.